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Tendon injuries occur commonly in horses and their repair through scar tissue formation
predisposes horses to a high rate of re-injury. Pluripotent stem cells may provide a cell
replacement therapy to improve tendon tissue regeneration and lower the frequency of
re-injury. We have previously demonstrated that equine embryonic stem cells (ESCs)
differentiate into the tendon cell lineage upon injection into the damaged horse tendon
and can differentiate into functional tendon cells in vitro to generate artificial tendons.
Induced pluripotent stem cells (iPSCs) have now been derived from horses but, to date,
there are no reports on their ability to differentiate into tendon cells. As iPSCs can be
produced from adult cell types, they provide a more accessible source of cells than
ESCs, which require the use of horse embryos. The aim of this study was to compare
tendon differentiation by ESCs and iPSCs produced through two independent methods.
In two-dimensional differentiation assays, the iPSCs expressed tendon-associated genes
and proteins, which were enhanced by the presence of transforming growth factor-β3.
However, in three-dimensional (3D) differentiation assays, the iPSCs failed to differentiate
into functional tendon cells and generate artificial tendons. These results demonstrate the
utility of the 3D in vitro tendon assay for measuring tendon differentiation and the need for
more detailed studies to be performed on equine iPSCs to identify and understand their
epigenetic differences from pluripotent ESCs prior to their clinical application.
Keywords: equine, embryonic stem cells, induced pluripotent stem cells, tendon, differentiation
INTRODUCTION
Tendon injuries account for up to 46% of all limb injuries in racing Thoroughbreds (1) and
commonly occur in other competition horses (2, 3). Injuries heal through the formation of scar tissue
which is biomechanically inferior to healthy tendon and predisposes horses to a high re-injury rate
of up to 67% (2). Tendon injuries are therefore the number one reason for retirement from racing
(4) and have a significant welfare impact.
Mesenchymal stem cells (MSCs) are being used increasingly for the treatment of tendon injuries
in horses (5). Currently, the therapeutic administration of MSCs uses autologous cells. Bone
marrow must be aspirated from each horse, with the associated risks and potential complica-
tions (6) of a relatively invasive procedure, followed by 2–4weeks for MSC culture expansion.
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This process precludes the treatment of acute injuries and makes
it difficult to standardize. As a result, in recent years, attention has
turned toward the use of allogeneic stem cells which could provide
an “off the shelf ” treatment. Numerous studies have demonstrated
the in vitro (7–10) and in vivo (11–15) safety of allogeneic MSCs.
However, we and others have previously demonstrated that MSCs
have a poor survival in the injured equine tendon (15, 16) and
so are likely to function through trophic effects rather than direct
differentiation.
Embryonic stem cells (ESCs) have been isolated from the inner
cell mass of equine blastocysts (17, 18) and following their injec-
tion into the injured equine tendon have a high survival without
inducing a cell mediated immune response or undergoing uncon-
trolled proliferation (15). The ESCs appear to undergo tenocyte
differentiation in vivo (19) and can differentiate in vitro into
functional tenocytes in response to transforming growth factor-
β3 (TGF-β3) and three-dimensional (3D) culture in a collagen
matrix (19, 20). Equine ESCs and their spontaneously differenti-
ated derivatives are immune privileged in vitro (9) and may there-
fore provide an allogeneic source of cells for use in regenerative
therapies to aid tendon tissue repair.
More recently, equine induced pluripotent stem cells (iPSCs)
have been derived by us (21) and others (22, 23) through the
overexpression of pluripotency factors in differentiated cells. Like
ESCs, equine iPSCs can proliferate indefinitely in vitro, differ-
entiate into derivatives of all three germ layers and may also
be immune privileged (24). However, unlike ESCs they do not
require the destruction of an embryo for their isolation, which
makes them more accessible to researchers. The potential of
equine iPSCs to be used as a source of cells, such as neurons, for
cell replacement therapies is therefore being investigated (25).
In this project, our aim was to determine if iPSCs generated
by two independent methods, using piggybac transposons and
retroviral vectors, responded to the same signaling mechanisms
as ESCs and could differentiate into functional tendon cells with
a similar efficiency.
MATERIALS AND METHODS
This study was carried out in accordance with the recommen-
dations of Animal Health Trust Ethical Review Committee. The
protocol was approved by the Animal Health Trust Ethical Review
Committee (02_2012).
ESC Culture
Three lines (i.e., derived from three different individuals) of pre-
viously characterized ESCs (9, 15, 17–20) were used in this study.
ESCs were cultured on mitotically inactivated mouse embry-
onic fibroblasts at 37.5°C, 5% CO2 as previously described (19).
Briefly, cells were cultured in ESC medium [Dulbecco’s modi-
fied Eagle medium (DMEM)/F12 containing 15% fetal bovine
serum, 2mM -glutamine, 1% non-essential amino acids, 1mM
sodium pyruvate, 0.1mM 2-mercaptoethanol (all from Invitro-
gen, Renfrewshire, UK), and 1000U/ml leukemia inhibitory fac-
tor (LIF) (Sigma, Dorset, UK)]. ESCs were passaged mechanically
every 5–7 days in the presence of 2μM Thiazovivin (StemGent,
Cambridge, MA, USA). ESCs were used at passage 12–24 for all
tendon differentiation studies.
iPSC Generation and Culture
Three lines of previously characterized (21, 24) iPSCs derived
from equine fetal fibroblasts using piggybac (PB) transposons
were used in this study and cultured as previously described
(21). Media consisted of DMEM high glucose supplemented
with 2mM GlutaMax™, 0.1mM non-essential amino acids,
0.1mM 2-mercaptoethanol, 1mM sodium pyruvate, 50U/ml
penicillin/streptomycin, 15% fetal bovine serum (all from Invit-
rogen), 1000U/ml LIF (Sigma), 10 ng/ml bFGF (Peprotech, NJ,
USA), 1.5μg/ml doxycycline (Sigma), 3μM GSK inhibitor, 0.5M
MEK inhibitor, 2.5μM TGF inhibitor, and 2μM thiazovivin (all
from StemGent).
Three lines of iPSCs were also generated from equine fibrob-
lasts by retroviral transduction using methods as reported pre-
viously (26). Fibroblasts were isolated from skin biopsies of two
adult horses at postmortem and from the limb buds from one,
day 35 horse embryo. Tissue was dissected into small pieces
prior to incubation inmedia [DMEMhigh glucose, supplemented
with 10% fetal calf serum, 1% penicillin–streptomycin, 2mM
-glutamine, and 1% fungizone (all from Invitrogen) and con-
taining 1mg/ml collagenase type I from Clostridium histolyticum
(Sigma)] at 37°C overnight. Cells were then resuspended in nor-
mal cell culture media (as above but without fungizone) and
cultured in a 10-cm plate at 37°C, 5% CO2 until confluent.
Fibroblast cells were passaged at confluency with trypsin-EDTA
(Sigma) for expansion, and stocks were frozen in media with
10% DMSO. iPSC generation was performed as described in Ref.
(26). Briefly, 4 105 packaging cells (phoenix gag-pol cells) were
plated onto five 6 cm plates (in DMEM, 10% fetal calf serum,
2mM -glutamine) and incubated overnight at 37°C, 5% CO2
prior to transfection with plasmid vectors containing 3μg of
one of the following human transcription factors: pMXs.hOct 4
(Addgene 17217), pMXs.hSox2 (Addgene 17218), pMXs.hKlf4
(Addgene 17219), and pMXs.hc-myc (Addgene 17220), or with
3μg of pMX.GFP (Cell Biolabs) to monitor efficiency of the
initial transfection of the packaging cells and the subsequent
viral transduction of the equine cells. The viral vectors were
pseudotyped with the VSVg envelope protein by including 3μg
of pVPack-VSV-G (Stratagene, Cheshire, UK) to each trans-
fection reaction. Transfections were carried out using lipofec-
tamine 2000 and Opti-MEM media (both Invitrogen) according
to the manufacturer’s instructions. After 24 h, the percentage of
GFP positive cells was calculated in a minimum of 10 random
fields to calculate the transfection efficiency of the packaging
cells.
After 48 h culture supernatant containing the viral particles
was filtered through a 0.45-μM filter (Nalgene). Filtered super-
natant from each transfected plate was pooled, supplemented with
1μg/ml polybrene (Sigma) and used to infect the equine skin
fibroblasts which had been plated at a density of 1 104 the
day before infection. Three rounds of viral infection were carried
out at 48 h intervals. The efficiency of viral transduction of the
fibroblasts was determined by calculating the percentage of GFP
positive cells in a minimum of 10 random fields. Four days after
the last infection, 5 103 equine cells were plated onto 10 cm
plates pre-seeded with feeder cells (mitotically inactivated mouse
embryonic fibroblasts). A proportion of the infected equine cells
were plated directly onto gelatin-coated coverslips and fixed for
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immunocytochemistry after 48 h to confirm the expression of the
human-reprograming factors in the infected cells.
Two days after plating the equine fibroblasts onto feeders,
the media were replaced with iPSC media [DMEM/F12, sup-
plemented with 15% FCS, 2mM -glutamine, 1% non-essential
amino acids, 1mM sodium pyruvate, 0.1mM 2-mercaptoethanol
(all Invitrogen), 1000U/ml LIF (Sigma), and 10 ng/ml basic
fibroblast growth factor (bFGF, Peprotech)]. iPSC media were
replaced every other day until iPSC colonies began to appear
(approximately 3 days after adding iPSC media). About 5–10 days
after becoming apparent, when they had reached a large enough
size, a pulled Pasteur pipette was used to manually pick selected
colonies. These colonies were expanded in six-well plates pre-
seededwith feeders in iPSCmedia, andmedia were replaced every
other day. When the colonies had reached a sufficient size, they
were mechanically passaged.
Induced pluripotent stem cells were cultured for more than 20
passages with repeated freeze/thaw cycles carried out. Freezing
was done using iPSC media containing 10% DMSO. iPSCs were
used at passage 3–13 for all tendon differentiation studies.
Karyotyping
The cells were incubated for 2 h at 37°C in media containing
colcemid (0.13μg/ml, Life Technologies, CA, USA) before har-
vesting with trypsin. The cells were suspended in 4ml of 0.075M
KCl and incubated at 37°C for 25min. Ten drops of fixative (3:1
methanol:acetic acid) were added, inverted to mix and incubated
at room temperature for 10min. Following centrifugation, the
cells were resuspended in 4ml of fixative and incubated at room
temperature for 30min. The cells were then centrifuged again,
and the pellet resuspended in 2ml of fixative before chromosomes
were visualized using DAPI staining.
Two-Dimensional Differentiation
Two-dimensional (2D) differentiation studies were performed
as detailed in Ref. (19, 26). Briefly, pluripotent stem cells were
induced to differentiate by passaging onto gelatin-coated cover-
slips (Sigma) without feeder cells and in media lacking LIF, bFGF,
doxycycline, and inhibitors. For spontaneous differentiation, the
cells were cultured for 7–14 days before being fixed and used
in immunocytochemistry. For tendon differentiation, cells were
cultured for 3 days to allow their attachment before the addition of
20 ng/ml TGF-β3 (PeproTech). The differentiating cells were then
harvested forRNAafter 1, 3, 7, or 14 days as detailed belowor fixed
and used in immunocytochemistry after 7 days. Differentiation
(spontaneous and tendon) was performed on three lines of each
pluripotent cell type.
Immunocytochemistry
Cells were cultured on gelatin-coated (Sigma) coverslips and fixed
in 3% paraformaldehyde in PBS for 20min at room temperature
prior to permeabilization for 1 h with 0.1% triton-X-100 at room
temperature. They were then washed thoroughly in PBS and
incubated with the primary antibodies overnight at 4°C, before
detection with an appropriate fluorescently labeled secondary
antibody. All antibodies were used at optimized concentrations
in PBS, and appropriate negative controls were performed using
secondary antibodies alone and IgG matched to the host species
and specific isotype of the primary antibody. To provide positive
controls for the pluripotency markers, we used equine ESCs (17).
Coverslips were mounted using Vectashield Hardset mounting
medium containing DAPI (40,6-diamidino-2-phenylindole, Vec-
tor Laboratories, Cambridge, UK). Primary antibodies included:
rabbit anti-alpha-fetoprotein 1:500 (Biorbyt, Cambridge, UK),
mouse anti-actin 1:200 (Dako, Cambridge, UK),mouse anti-Beta-
III tubulin 1:100 (Sigma), mouse anti-SSEA-4 1:100 (Chemicon,
Hampshire, UK), mouse anti-SSEA-1 1:100 (Chemicon), rat anti-
SSEA-3 1:100, mouse anti-TRA-1-60 1:500 and mouse anti-TRA-
1-81 1:500 (both kindly provided by Prof. Peter Andrews at
the University of Sheffield, UK), rabbit anti-Oct-4 1:100 (Santa
Cruz Biotechnology, CA, USA), rabbit anti-Klf-4 1:50 (Abcam,
Cambridge, UK), rabbit anti-c-myc 1:100 (Abcam), rabbit anti-
Sox-2 1:1000 (Abcam), rabbit anti-scleraxis 1:100 (Abcam), rabbit
anti-tenascin-C 1:100 (Abcam), rabbit anti-tenomodulin 1:100
(Santa Cruz), mouse anti-collagen I 1:100 (Abcam), rabbit anti-
thrombospondin-4 1:100 (Santa Cruz), and rabbit anti-COMP
1:500 (kindly provided by Professor Roger Smith, Royal Vet-
erinary College, UK). Secondary antibodies included goat anti-
mouse FITC 1:200 (Abcam), goat anti-rabbit FITC 1:100 (Sigma),
goat anti-rabbit alexafluor 594 1:200 (Invitrogen), goat anti-mouse
alexafluor 594 1:200 (Invitrogen), and goat anti-rat Texas Red
1:200 (Sigma).
Alkaline phosphatase was detected using the Chemicon kit
according to the manufacturer’s instructions.
RNA Extraction, cDNA Synthesis, and
Quantitative PCR
This was performed as described previously (20). RNA was
extracted using Tri-reagent (Sigma) and treated with Ambion
DNA-free (Life Technologies, Paisley, UK). cDNAwas made from
1μg of RNA using Moloney murine leukemia virus reverse tran-
scriptase (Promega, Hampshire, UK) with oligo(dT) and ran-
dom hexamers as primers (both Promega). About 2μl aliquots
of cDNA were used in quantitative PCR (qPCR). Primers were
designed using primer31 and mfold2 to obtain amplicons with
a melting temperature (Tm) of 58–62°C, devoid of secondary
structure at Tm 60°C and with an amplicon size of 50–150 bp.
Primer sequences can be found in Table 1. qPCR was carried out
using SYBR Green containing supermix (Bioline, London, UK)
on a Quantica machine (Techne, Staffordshire, UK). All PCRs
were performed in duplicate. PCR cycle parameters were 95°C
for 10min, followed by 40 cycles of 95°C for 15 s, 60°C for 15 s,
and 72°C for 15 s. At the end of the program, a melt curve was
produced by taking readings every 1°C from 65 to 95°C. 18s
rRNA levels did not change between treatments (data not shown)
and was used to normalize gene expression using the 2 ΔΔCt
method (27). A Student’s t-test was used to determine statistically
significant fold changes in gene expression between the control
and treated groups at each time point. qPCR was performed on
three lines of iPSCs and ESCs.
1http://frodo.wi.mit.edu/primer3
2http://mfold.rna.albany.edu/?q=mfold/DNA-Folding-Form
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TABLE 1 | Primer sequences for equine gene transcripts.
Gene Forward Reverse
18s rRNA CCCAGTGAGAATGCCCTCTA TGGCTGAGCAAGGTGTTATG
Scleraxis CCCAAACAGATCTGCACCTT ATCCGCCTCTAACTCCGAAT
Tenascin-C AACCCGTCCAAAGAGACCTT GCGTGGGATGGAAGTATCAT
Tenomodulin GTCCCTCAAGTGAAGGTGGA CCTCGACGGCAGTAAATACAA
Collagen
type-1 alpha 1
TGCGAAGACACCAAGAACTG GACTCCTGTGGTTTGGTCGT
Cartilage
oligomeric
matrix protein
AGAACATCATCTGGGCCAAC CGCTGGATCTCGTAGTCCTC
Thrombos
pondin-4
GGGAAATGGGGTTACCTGTT CGGGTAGCAGGGATGATATT
Three-Dimensional Differentiation
For embryoid body formation, the iPSCs were passaged onto low
attachment plates (Corning Life Sciences, MA, USA) in media
without feeders, LIF or bFGF. Embryoid body formation was
monitored for 14 days; media was changed every 3 days.
For tendon differentiation, 0.2mm diameter minutien pins
were embedded in silicone-coated 6-well plates (Sylgard 184
Silicone elastomer, Dow Corning, USA) in pairs 15mm apart.
Mechanically passaged iPSCs were isolated, and a small aliquot
was dissociated with TrypLE™ Express (Invitrogen, Renfrewshire,
UK) to generate representative cell counts. Colonies of iPSCs
were suspended in a chilled mixture of two parts iPSC medium
(without LIF, bFGF) and eight parts PureCol (Bovine collagen
type I, Advanced Biomatrix, USA) (with the pH adjusted to
7.2–7.6) at 4 105 cells/ml. About 200μl of collagen-iPSC suspen-
sionwas pipetted between each pair ofminutien pins. The six-well
plates were then incubated at 37.5°C for 60–90min to allow the
constructs to set. After setting, 3ml of iPSC medium (without
LIF/FGF) was added to each well, with or without 20 ng/ml (19,
20) TGF-β3. Constructs were cultured for up to 28 days and
during this time the media was changed every 3–4 days.
Contraction Analysis
The 3D constructs were photographed daily and the images ana-
lyzed using ImageJ software (National Institutes of Health, USA).
Individual images were calibrated using the well diameter. For
each construct, three measurements were made across the width
and averaged. Contraction of the constructs was calculated as a
percentage of the Day 0 value. A Student’s t-test was used to deter-
mine statistically significant differences in contraction between
ESCs and iPSCs. For contraction analysis, repeats were performed
on three independent lines of ESCs and iPSCs with a minimum
of two technical repeats carried out for each cell line. For each
technical repeat, a minimum of three constructs were measured
at each time point for each condition.
Cell Survival Assay
Constructs were harvested and digested in 1ml medium with
1mg/ml type I collagenase produced by C. histolyticum (Sigma)
for 1–2 h at 37.5°C. The digest was pelleted by centrifugation and
resuspended in 1ml TrypLE™ Express (Invitrogen, Renfrewshire,
UK) and also kept at 37.5°C in order to fully dissociate the cells.
Cell counts were performed on a hemocytometer, and results are
displayed as a percentage of the seeded cell number on Day 0.
A Student’s t-test was used to determine statistically significant
differences in cell survival. Cell survival was performed using
three independent cell lines of ESCs or iPSCs. For each line, a
minimum of two constructs was used to calculate the cell survival
at each time point for each condition.
Histology on 3D Constructs
As described previously (20), constructs containing ESCs were
embedded in OCT compound (VWR, PA, USA) and snap frozen
in liquid nitrogen cooled-isopentane. A cryostat was used to cut
longitudinal sections of 11μm thickness. The sections were fixed
in 100% acetone for 10min and stored at  20°C until used.
Histological staining was carried out using hematoxylin and eosin
(H&E) to view the distribution and morphology of the cells.
RESULTS
Generation and Characterization of
Equine iPSCs From Adult Fibroblasts
Using Retroviral Transduction
As expected, the efficiency of transfection of the packaging cells
was high with>90% of the cells expressing GFP (data not shown).
We found that repeated rounds of retroviral infection of the equine
cells led to increased levels of GFP, with a maximum of approxi-
mately 80% being reached after three rounds of infection (Figure
S1 in Supplementary Material). After three rounds of infection,
a proportion of cells were used in immunocytochemistry which
confirmed the expression of all four pluripotency reprograming
factors in the equine cells (Figure S2 in Supplementary Mate-
rial). Approximately 5 days after plating the infected equine cells
onto feeders, it could be seen that a small proportion of the
cells had a distinct change in their cellular morphology; going
from a fibroblastic shape to forming colonies of small round cells
(Figures 1Ai,Aii). Over the following days in culture the colonies
increased in size and number and were selected and mechanically
picked from the fibroblast culturewhen theywere clearly visible by
eye. The colonies themselves were flat, resembling human iPSCs
and equine ESCs, and contained cells which had a high nuclear
to cytoplasmic ratio. The equine iPSCs could be expanded for
over 20 passages using mechanical passaging. During this time,
the iPSCs showed no loss of their proliferative potential, with
the time between passages remaining constant (5–7 days) as the
passage number increased. The iPSCs could also be frozen and
thawed with no change in their characteristics. From passage five,
in media containing LIF and bFGF, the retroviral-derived iPSCs
began to silence the expression of the integrated reprograming
factors. This was visualized by a lack of GFP fluorescence in the
iPSC colonies (Figures 1Bi,Bii).
Immunocytochemistry on later passage cells (>5) continued
to demonstrate positive staining of the undifferentiated iPSCs for
pluripotencymarkersOct 4, TRA-1-60, TRA-1-81, SSEA-4, SSEA-
3, and SSEA-1, and staining for alkaline phosphatase activity
was detected (Figures 2Ai–Gi). Together, this suggests that while
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FIGURE 1 | Generation of equine iPSCs using retroviral overexpression
of pluripotency genes. (Ai) Equine skin fibroblasts express GFP in a high
percentage of cells after retroviral transduction (Bi). (Aii) Shows an iPSC
colony which has silenced the exogenous retroviral genes and lost GFP
expression (Bii). Scale bar= 40μm.
FIGURE 2 | Undifferentiated iPSCs express pluripotency markers
(Ai–Gi) which are lost upon spontaneous differentiation (Aii–Gii).
Negative controls on the undifferentiated cells for the secondary antibodies are
shown in (H) anti-mouse, (I) anti-rabbit, and (J) anti-rat. Scale bar= 40μm.
FIGURE 3 | Induced pluripotent stem cells can undergo differentiation
in vitro. After 7 days of spontaneous in vitro 2D differentiation,
immunocytochemistry demonstrates positive staining for βIII tubulin, actin,
and alpha-fetoprotein (Ai–Ci). These proteins are not produced by the
undifferentiated iPSCs (Aii–Cii). Negative controls on the differentiated cells
are shown in (D,E). Scale bar= 40μm. The iPSCs can also form cystic
embryoid bodies in suspension culture over a period of 14 days (F).
the exogenous reprograming factors are silenced, the endoge-
nous pluripotency factors remain expressed. After spontaneous
in vitro differentiation of the iPSCs for 7 days, the expression of
all pluripotency markers was lost (Figures 2Aii–Gii). Further-
more, after this time, immunocytochemistry-detected differenti-
ation into cells derived from all three germ layers: α-fetoprotein
positive fetal liver cells (endoderm), actin positive muscle cells
(mesoderm), and β-III tubulin positive neuronal cells (ectoderm)
(Figures 3Ai–Ci) which were not produced by the undifferenti-
ated cells (Figures 3Aii–Cii) or the negative controls (Figures 3D,
E). When plated onto low attachment plates in media without LIF
or bFGF the iPSCs able to form cystic embryoid bodies over a
period of 14 days (Figure 3F). Karyotype analysis of the iPSCs
confirmed that they had a normal chromosome number (n= 64,
Figure 4).
iPSCs Generated by Different Methods
Have a Similar Response to TGF-β3 in 2D
Culture, But This Appears to Be Delayed
Compared to ESCs
Undifferentiated iPSCs derived by either method do not express
any tendon-associated genes or proteins (data not shown) but
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exhibit a similar response in their tendon gene expression profiles
upon the induction of differentiation in the absence and presence
of TGF-β3 (Figure 5). Retroviral iPSCs, piggybac iPSCs, and ESCs
all fail to demonstrate detectable expression of THBS4 at any
FIGURE 4 | Induced pluripotent stem cells have a normal karyotype of
n=64 as shown by DAPI staining of metaphase chromosome spreads.
FIGURE 5 | Induced pluripotent stem cells generated by two independent methods show a similar expression profile of tendon-associated genes
following 2D differentiation in the presence of TGF-β3. But they are delayed in comparison to ESCs. Expression is shown as the fold change in TGF-β3-treated
cells compared to cells differentiating in the absence of TGF-β3. *p<0.05;  , expression not detected; induced, expression only detected in TGF-β3-treated cells.
time point during the differentiation process in either control or
TGF-β3 treated cells. In contrast, COL1A1 is expressed in control
and TGF-β3 treated cells in all cell types at all time points after the
induction of differentiation. However, for all other tendon genes,
there appears to be some differences between ESCs and iPSCs. The
ESCs express TNMD throughout their differentiation, whereas
neither type of iPSCs expressed detectable TNMD at any time
during their differentiation. TNC is expressed in both control and
TGF-β3-treated ESCs at all time points studied, whereas its detec-
tion is more variable in the iPSCs, only appearing in both control
andTGF-β3-treated cells in both retroviral and piggybac cells after
14 days. COMP expression is also robust in control and TGF-β3
ESCs at all time points but is only detected in TGF-β3-treated
piggybac iPSCs not control cells at any time point. However, after
14 days in the presence of TGF-β3, the relative expression levels
of the expressed genes are not significantly different between the
ESCs and iPSCs (data not shown).
Immunocytochemistry performed after 7 days of differentia-
tion in the presence or absence of TGF-β3 (Figure 6) supports
the gene expression data and demonstrates that iPSCs generated
by either method show a similar protein expression profile after
7 days of culture in the presence of TGF-β3. Unlike the ESCs,
the iPSCs do not express any detectable levels of TNMD. TNC
and COMP are more strongly detected in the TGF-β3 group in
both iPSC types, but COL1A1 is strongly detected in control and
TGF-β3 in both iPSC types.
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FIGURE 6 | Immunocytochemistry for protein expression in the iPSCs generated through piggybac transposons or retroviral vectors demonstrates
largely similar profiles after 7 days of culture in the presence of TGF-β3 and supports the gene expression data. Unlike the ESCs, neither type of iPSCs
expresses TNMD protein. Scale bar=40μm.
ESCs Generate Artificial Tendons in
3D Culture More Efficiently Than iPSCs
As the iPSCs derived from retroviral transduction of adult
fibroblasts behaved similar to iPSCs derived from fetal fibrob-
lasts by transposons, only the retrovirally generated iPSCs were
used in 3D cultures. ESCs cultured in a 3D collagen gel form
artificial tendons that are indistinguishable from those gener-
ated by adult tenocytes over a period of 14 days (20). iPSCs
cultured in 3D collagen gels undergo significantly slower re-
organization of the collagenmatrix thanESCs (Figure 7).Whereas
ESCs have contracted the matrix to the maximum (approxi-
mately 20% of its starting size) after 14 days, iPSCs fail to reach
maximum contraction even after 28 days of culture. ESCs cul-
tured in 3D in the presence of TGF-β3 have an enhanced rate
of early tendon differentiation (20), but TGF-β3 has no sig-
nificant effect on the contraction rate of 3D gels containing
iPSCs.
The lower rate of contraction by iPSCs is not due to a low
survival of the cells. In contrast, they exhibit high survivals of
between 75 and 140% at all time points studied (Figure 8). TGF-
β3 does not have any significant effect on the survival of the
iPSCs (Figure 8A), and their survival is not significantly dif-
ferent to that of ESCs at the time points up to 14 days which
could be compared [Figure 8B; ESCs cannot be cultured in
3D beyond 14 days as they snap off the posts due to their
contraction (20)].
iPSCs Remain in Cell Clusters During
3D Culture
The lack of contraction of the iPSC-seeded 3D constructs meant
that the constructs were too insubstantial for sectioning and
so precluded analysis via histological and immunohistochemical
studies. However, the iPSCs, like ESCs, were seeded as cell clusters
in the 3D collagen gels. Image analysis of the iPSCs in culture
demonstrated that even after 28 days in the 3D environment, all
iPSCs remained in the initial clusters of cells (Figure 9A). Some
of the iPSC clusters demonstrated fibroblastic outgrowths, but
these occurred in all directions and did not specifically align to
the direction of the intrinsic force. In contrast, H&E staining of
ESC-seeded 3D constructs demonstrates that the majority of cells
migrate to the outer edges of the construct and align with the
direction of force (Figures 9Bi,Bii). Occasional clusters of cells
remain in some gels (Figures 9Ci,Cii), but these are rare.
The iPSCs in 3D culture remainGFPnegative (data not shown),
suggesting that they have not re-activated the exogenous viral
genes.
iPSCs in 3D Culture Have Low Levels of
Tendon Gene Expression in Comparison to
ESCs
qRT-PCR analysis has demonstrated a robust expression of
tendon-associated genes in ESC collagen gels after 7 and 14 days
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FIGURE 7 | Induced pluripotent stem cells are less efficient at remodeling a 3D collagen gel than ESCs. ESC-seeded constructs reach their maximum
contraction after 14 days of culture, whereas iPSC-seeded gels display limited contraction even after 28 days of culture.
that was much greater than the expression levels in 2D differen-
tiation assays (20). In iPSC collagen gels cultured for 28 days in
the presence or absence of TGF-β3, we could not detect robust
expression of any tendon-associated genes examined with the
exception of COL1A1. COL1A1 was expressed at very high levels
in iPSCs cultured in 3D gels for 28 days, and its expression was not
significantly affected by the addition of TGF-β3 (Figure 10A). In
comparison to iPSCs differentiated for 14 days in 2D culture in the
absence of TGF-β3, 3D culture for 28 days resulted in a 110-fold
increase in COL1A1 expression. This is significantly greater than
the 31-fold increase in COL1A1 expression which occurs when
ESCs are cultured in 3D for 14 days as opposed to 2D for 14 days
(Figure 10B).
DISCUSSION
There are a number of safety issues that must be addressed prior
to the clinical application of pluripotent equine stem cells. As
ESCs are derived from early embryos, any future clinical appli-
cation will rely on using allogeneic cells. Although we have shown
promising data supporting the application of allogeneic ESCs (9,
15) further immunological assessments must be performed for
specific tissue injuries where different differentiated cell types
and different inflammatory environments may result in different
immune responses to allogeneic cells. Although iPSCs can be
derived from patients for autologous use, the time scales and
expense required to do this is likely to prevent it as a treatment
option. As for ESCs, there is promising data on the potential to use
allogeneic equine iPSCs, but further research must be performed
(24). Human iPSCs have already been taken forward to clinical
trial for macular degeneration in Japan, and there is much hope
that equine iPSCs will also be of clinical benefit for a range of
conditions. However, to date, all equine iPSCs have been derived
with integrating DNA sequences which leads to safety concerns
if these sequences have the potential to become re-expressed
(28) and the use of other strategies, which have successfully
been employed to generate human iPSCs, using non-integrating
viruses, mRNA and protein (29) need to be investigated in the
horse.
Here, we compared iPSCs produced by piggybac transposons
(21) and retroviral vectors. The retrovirally produced iPSCs gen-
erated colonies with the same morphology as transposon pro-
duced iPSCs and equine ESCs. Within a few passages, the retro-
virally transduced iPSCs appeared to have silenced the expres-
sion of the exogenous viral genes, as assessed by a loss of GFP
expression, which is one of the hallmarks of the pluripotent
state (30). In contrast, the piggybac iPSCs rely on the addition
of doxycycline to maintain the expression of the reprogram-
ing factors to keep the cells in the undifferentiated state (21).
The retrovirally generated iPSCs express the same profile of
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FIGURE 8 | Induced pluripotent stem cells have a high survival in the
3D constructs at all time points measured. (A) The presence of TGF-β3
has no significant effect on the survival of the iPSCs. (B) There are no
significant differences between the survival of ESCs and iPSCs up to 14days
of culture.
pluripotency markers as equine ESCs (17), transposon-derived
iPSCs (21) and the inner cell mass of equine embryos (17).
Therefore, thesemarkers would appear to be suitable pluripotency
markers in equine cells. The retrovirally derived iPSCs also dis-
play the same ability for in vitro differentiation into derivatives
of the three germ layers as equine ESCs (18) and transposon-
derived iPSCs (21). Therefore, the method of iPSC generation
used and the age of the donor fibroblasts (fetal or adult) do not
appear to impact on the key pluripotency characteristics of the
cells.
In order to determine the clinical potential of equine iPSCs to
be used as a source of cells in tendon regeneration, we assessed
their capacity for in vitro differentiation into functional tendon
cells using the same signaling molecules and protocols which we
have established for equine ESCs (19, 20). The iPSCs derived by
transposons and retroviral transduction express the same tendon
genes upon 2D differentiation over a 14-day time period, and
this is enhanced with TGF-β3. This suggests that the method of
generation and the age of the fibroblast donor (fetal or adult) do
not influence the tendon differentiation capacity of the iPSCs. The
iPSCs appear to be less efficient at undergoing TGF-β3-driven
differentiation in 2D culture in comparison to the ESCs. The
ESCs express tendon-associated genes much more quickly than
the iPSCs, and the iPSCs fail to express TNMD at any time point
studied. Interestingly, the ESCs and iPSCs do appear to express
tendon-associated genes in a similar order. In both ESCs and
iPSCs, tendon genes, such as SCX andTNC are first detected along
with COL1A1 suggesting that these are earlier markers of tendon
differentiation than TNMD and THBS4.
We have previously shown that 3D culture is a potent driver of
tendon differentiation by ESCs (20). We therefore hypothesized
that, upon exposure to a combination of 3D culture and TGF-β3,
the iPSCs would have a similar capacity for tendon differentiation
and the generation of artificial tendons as ESCs. However, we
found that iPSCs re-organize a 3D collagen gel at a significantly
slower rate than ESCs. ESCs and adult tendon cells both reach
their maximum contraction of the 3D collagen gels in 14 days and
if left longer than this will snap off their posts (20, 31). However,
even after 28 days of culture, the iPSC-containing gels did not
undergo a large amount of contraction. The iPSCs survived in
equivalent numbers to the ESCs, and so the lack of contractionwas
not simply due to a lack of survival of the cells. The iPSCs survived
in constant numbers over the 28 days’ time period studied. This
may reflect a constant rate of cell proliferation and death, or
a partially differentiated state which does not undergo further
proliferation or death. Future work using assays to determine
levels of cell proliferation rather than just survival would be of
benefit in understanding the fate of the iPSCs in 3D culture. As
we previously observed for ESCs (20), the survival of the iPSCs
was not significantly affected by the presence of TGF-β3. The
iPSCs remained in cell clusters as they had been seeded and
did not migrate out throughout the gel like the ESCs. We were
unable to detect robust expression of any of the tendon-associated
genes which they expressed in 2D cultures, with the exception
of COL1A1 which was significantly upregulated in 3D culture
compared to 2D culture. Although the increase in expression of
COL1A1 in 3D culturewas significantly greater than that observed
for ESCs, this may reflect the length of culture as iPSCs were left
for 28 days, whereas ESCs were only left for 14 days in 3D culture.
The iPSCs in 3D cultures remained GFP negative, suggesting that
the reprograming factors had not been re-activated. However, it
remains possible that exogenous GFP could remain silenced while
some or all of the exogenous pluripotency factors become re-
expressed, and this could hinder the differentiation of the iPSCs
in 3D. Future work to determine the expression of the exogenous
reprograming genes would help determine if this was the case.
Together, this suggests that the iPSCs do not efficiently undergo
tendon differentiation in 3D cultures, instead remaining in a
partly undifferentiated state. To further identify the state of the
iPSCs, global gene expression analysis would be of great benefit
to look at the expression of genes involved in pluripotency and
commitment to all lineages.
This study therefore highlights the disadvantages of using gene
and protein expression in 2D culture alone as a marker of success-
ful differentiation as, after 14 days in the presence of TGF-β3, the
iPSCs showed a largely comparable expression profile of tendon
genes to the ESCs, and yet we were unable to demonstrate the
functionality of the iPSC-derived tenocytes in remodeling a colla-
genmatrix.We have therefore shown that our 3D culture system is
a useful model to test tendon cell functionality, which is an impor-
tant assay in addition to gene and protein expression studies. To
date, we have not established the methodology for selecting the
tenocytes from themixed population of differentiating cells which
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FIGURE 9 | Induced pluripotent stem cells remain in cell clusters in 3D gels. (A) iPSCs in 3D constructs at 28 days remain in cell clusters. Some clusters
demonstrate fibroblastic outgrowths, but these are not specifically aligned to the direction of force (arrow). (Bi) In contrast, H&E-stained sections of ESC 3D
constructs after 14 days demonstrate that the majority of cells are at the edges of the gels and are evenly distributed. A higher magnification image is shown in (Bii).
(Ci) Occasional clusters of cells are still present in some ESC 3D constructs after 14 days. A higher magnification image is shown in (Cii). Scale bar= 100μm.
FIGURE 10 | COL1A1 gene expression by iPSCs in 3D culture.
(A) COL1A1 expression in iPSCs after 28 days of 3D culture is not significantly
affected by the addition of TGF-β3. (B) iPSCs cultured for 28 days in 3D
culture without TGF-β3 show a large fold increase in their expression of
COL1A1 compared to iPSCs differentiated in 2D culture for 14 days without
TGF-β3. This increase is significantly greater than that observed with ESCs
cultured in 3D cultures for 14 days without TGF-β3 compared to ESCs
differentiated in 2D culture for 14 days without TGF-β3.
arise in 2Ddifferentiating cultures.However, in the future it would
be of value to determine if these predifferentiated iPSCs derived
in 2D culture were able to function in 3D culture.
Numerous reports have demonstrated that human iPSCs have
a reduced differentiation efficiency compared to ESCs (32). This
may be because differentiation protocols have been established for
ESCs, and the signaling requirements of iPSCs are different. Itmay
also be related to the fact that iPSCs retain an epigenetic memory
of their origin (DNA methylation and/or histone modifications)
which can affect their differentiation potential, enhancing their
differentiation back to the cell type fromwhich they were derived,
and inhibiting their differentiation into other lineages (33, 34).
These epigenetic changes have led to detectable changes in global
gene expression profiles between human ESCs and iPSCs (35–37).
In order to reduce the epigenetic memory of the iPSCs, prolonged
culture may be beneficial (34) and as this study used iPSCs at
fairly low passage (3–3), future work to examine the differen-
tiation capacity of iPSCs at higher passages may be warranted.
Performing the work on higher passage iPSCs may also result in
a lower chance that the exogenous reprograming factors become
re-expressed.
The results of this study highlight that there is still a need
to understand more about pluripotency in horses to determine
the mechanisms which underpin differences in differentiation
potential between varying sources of pluripotent stem cells and
how these differences may affect their clinical utility. Future work
to compare the global gene expression and methylation patterns
in ESCs versus iPSCs generated by different methods, including
through the use of non-integrating viruses, is much needed before
iPSCs can be taken forward as a clinical therapy.
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